|
Literature:
1.Topol EJ, Serruys PW. Frontiers in
interventional cardiology. Circulation 1998; 98: 1802-20
2.Fischman Dl, Leon MB, Baim Ds, et al. A randomized comparison of
coronary stent placement and balloon angioplasty in the treatment of
coronary artery disease: Stent Restenosis Study Investigators. N Engl J
Med 1994; 331: 496-501
3.Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of
balloon-expandable stent implantation with balloon angioplasty in
patients with coronary artery disease: Benestent Study Group. N engl J
Med. 1994; 331: 489-95
4. Topol EJ. Coronary-artery stents: gauging, gorging, and gouging. N
Engl J Med 1998; 339: 1702-4
5. Serruys PW, Foley DP, Suttorp M-J, et al. A randomized comparison of
the value of additional stenting after optimal balloon angioplasty for
long coronary lesions. J Am Coll Cardiol 2002; 39: 393-9
6. Van den Brand M, Rensing J, Morel MM, et al. The effect of
completeness of revascularization on event-free survival at one-year in
the ARTS trial. J Am Coll CArdiol 2002; 39: 559-64
7. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stenrs to
prevent occlusion and restenosis after transluminal angioplasty. N Engl
J Med 1987; 316: 701-6
8. El-Omar MM, Dangas G, Iakovou I, et al. Update on in-stent restenosis.
Curr Interv Cardiol Rep 2001; 3: 296-305
9. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy
to inhibit restenosis after coronary stent. N Engl J Med 1997; 336:
1697-703
10. Malhorta S, Teirstein PS. The SCRIPPS trial: catheter-based
radiotherapy to inhibit coronary restenosis. J Invasive Cardiol 2000; 12
(6) 330-2
11. Leon MB, Teirstein PS. Moses JW, et al. Localized intracoronary
gamma-radiation therapy to inhibit the recurrence of restenosis after
stenting. N Engl J Med 2001; 25; 344 (4):250-6
12. teirstein PS, Kuntz RE. New frontiers in interventional cardiology:
intravascular radiation to prevent restenosis. Circulation 2001 Nov. 20;
104 (21): 2620-6
13. Wiletz JR, Sanborn TA, Haudenschild CC, et al. Platelet accumulation
in experimental angioplasty: time course and relation to vascular
injury. Circulation 1987; (3): 636-42
14. Wilensky RI, March KL, Gradus-Pizlo I, et al. Vascular injury,
repair, and restenosis after percutaneous transluminal angioplasty in
the atherosclerosit rabbit. Circulation 1995; 92 (10): 2995-3005
15. Stoltenberg RL, Geraghty J, Steele DM, et al. Inhibition of intimal
hyperplazia in rat aortic allografts with cyclosporine. Tranplantation
1995; 60 (9): 993-8
16. Glagov S. Intimal hypeplasia, vascular modeling, and the restenosis
problem. Circulation 1994; 89:2888-91
17. Schwartz R, Holmes D, Topol E. The restenosis paradigm revisited: an
alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992;
20: 1284-93
18. Schwartz RS, Murphy JG, Edwards WD, et al. Restenosis after balloon
angioplasty: a practical proliferative model in porcine coronary
arteries. Circulation 1990: 82: 2190-200
19. Ross R, Wight TN, Strandness E, et al. Human atherosclerosis. I.
Cell constitution and characteristics of advanced lesions of the
superficial femoral artery, Am J Pathol 1984; 114: 79-93
20. Moses PRL, Campbell GR, Wang ZL, et al. Smooth muscle phenotypic
expression in human arteries. Lab Invest 1985; 53: 556-62
21. Austin GE, Ratliff NB, Hollman J, et al. Intimal proliferation of
smooth muscle cells as an explanation for recurrent coronary artery
stenosis after percutaneous transluminal coronary angioplasty. J Am Coll
Cardiol 1985; 6: 369-75
22. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation
after arterial injury. Lab Invest 1983; 49: 327-33
23. Schwartz SM, deBlois D, O’Brien ERM. The intima: soil for
atherosclerosis and restenosis. Circ Res 1995; 77: 445-65
24. Morishita R, Gibbons GH, Ellison KE, et al. Single intraluminal
delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen
oligonucleotides results in chronic inhibition of neointimal
hyperplasia. Proc Nat Acad Sci USA 1993; 90: 8474-8
25. Sirois MG, Simons M, Edelman BR, et al. Platelet release of platelet
derived growth factor is required for intimal hyperplasia in rate
vascular injury model [abstract] . Circulation 1994; 90 Suppl. 1:I-511
26. Mintz GS, Popma JJ, Hong MK, et al. Intravascular ultrasound to
discern device-specific effects and mechanisms of restenosis. Am J
Cardiol 1996; 78:18-22
27. Edelman ER, Rogers C. Pathologic responses to stenting. Am J Cardiol
1998; 81: 4E-6E
28. Komatsu R, Ueda M, Naruko T, et al. Neointimal tissue response at
sites of coronary stenting in humans: macroscopic, histological, and
immunohistochemical analyses. Circulation 1998; 98: 224-33
29. Kornowsky R, Hong MK, Tiio FO, et al. In-stent restenosis:
contributions of inflammatory responses and arterial injury to
neointimal hyperplasia. J Am Coll Cardiol 1998; 31:224-30
30. Jawien A, Bowen-Pope DF, Lindner V, et al. Platelet-derived growth
factor promotes smooth muscle migration and intimal thickening in a rat
model of balloon angioplasty. J Clin Invest 1992; 89: 507-11
31. Sriram V, Patterson C. Cell cycle in vasculoproliferative
diseases-potential interventions and routes of delivery. Circulation
2001; 103: 2414-9
32. Koster R, Vieluf D, Kiehn M, et al. Nickel and molybdenum contact
allergies in patients with coronaty in-stent restenosis. Lancet 2000;
356: 1895-7
33. Kipshidze N, Moses J, Shankar LR, et al. Perspectives on antisense
therapy for the prevention of restenosis. Curr Opin Molecular Ther 2001,
227
34. Herdeg C, Oberhoff M, Baumbach A, et al. Local Paclitaxel delivery
for the prevention of restenosis: biological effects and efficacy in
vivo. J Am Coll Cardiol 2000; 35 (7): 1969-76
35. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal
thickening after balloon angioplasty in porcine coronary areteries by
targeting regulators of the cell cycle. Circulation 1999; 99:2164-70
36. Suzuki T, Kopia G, Shin-ichiro H, et al. Stent-based delivery of
Sirolimus reduces neointimal formation in a porcine coronary model.
Circulation 2001; 104: 1188-93
37. Marx SO, Marks AR. Bench to bedside: the development of rapamycin
and its application to stent restenosis. Circulation 2001; 104:852-5
38. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating
inhibits neointimal hyperplasia at 4 weeks in a porcine model of
coronary restenosis. Circulation 2001 May; 103 (18): 2289-95
39. Schink JC, Singh DK, Rademaker AW, et al. Etoposide, methotrexate,
actinomycin cyclophosphamide, and vincristine in the treatment of
metastatic, high-risk gestational trophoblastic disease. Obstet Gynecol
1992 Nov; 80 (5) 817-20
40. Bailey S. Local drug delivery during percutaneous coronary
intervention. Curr Interv Cardiol Rep 2000; 2 (4): 349-57
41. Oberhoff M, Herdeg C, Ghobainy R, et al. Local delivery of
Paclitaxel using the double-balloon perfusion catheter before stenting
in the porcine coronary artery. Catheter Cardiovasc Interv 2001 Aug; 53
(4): 562-8
42. Ettenson DS, Edelman ER. Local drug delivery: an emerging approach
in the treatment of restenosis. Vasc Med 2000; 5 (2): 97-102
43. Hofma SH, van Beusekom HM, Serruys PW, et al. Recent developments in
coated stents. Curr Interv Cardiol 2001 Feb; 3 (1): 2836
44. Xiaoshun L, Huang Y, De Scheeder I. Study of antirestenosis with the
biodivysiodexamethasone eluting stent (STRIDE): a multicenter trial. 51
Annual Scientific Session, Atlanta, GA. J Am Coll Cardiol 2002 Mar
17-20; 19, 5 Suppl A. 15A: 1052-7
45. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal
proliferation after implantation of Sirolimus-coated stents in human
coronary arteries: a quantitative coronary angiography and
three-dimensional intravascular study. Circulation 2001; 103 (2): 192-5
46. Sousa JE, Costa MA, Abizaid A, et al. Sustained supression of
neointimal proliferation by sirolimus-eluting stents: one-year
angiographic and intravascular ultrasound follow-up. Circulation 2001;
104 (17): 2007-11
47. Sousa JE, Morice MC, Serruys PW, et al. The RAVEL study: a
randomized study with the sirolimus coated BX velocity
balloon-expandable stent in the treatment of patients with de novo
native coronary artery lesions [abstract no. 2198]. Circulation 2001
Oct; 104 Suppl II: 17
48. Abizaid A, Serruys P, Abizaid A, et al. The absence of edge effect
after implantation of sirolimus-eluting stents to treat in-stent
restenosis: a three-dimensional intravascular ultrasound volumetric
analysis [abstract no. 1174-14]. J Am Coll Cardiol 2002 Mar 17-20; 39 (5
Suppl A): 58A
49. Degertekin M, Tanabe K, Regar E, et al. Are sirolimus-eluting stents
inducing vascular remodeling?: a subgroup analysis of 3D-intravascular
ultrasound in the RAVEL trial [abstract no. 1174-18]. J Am Coll Cardiol
2002 Mar 17-20; 39 (5 Suppl A): 59A
50. Moses JW, Leon MB, Popma JJ, et al. The US Multicenter, randomized,
double-blind study of the sirolimus-eluting stent in coronary lesions:
early (30-day) safety results [abstract 2200]. Circulation 2001 Oct;
Suppl II: 104
51. Park SJ, Won HS, Ho DS, et al. The clinical effectiveness of
paclitaxel-coated coronary stents for the reduction of restenosis in the
ASPECT trial [abstract 2199]. Circulation 2001 Oct; 104 Suppl II:17
52.Chevalier B, De Scheeder I, Gershlick A, et al. Effect on restenosis
with a paclitaxel eluting stent: factors associated with inhibition in
the elutes clinical study [abstract no. 1174-17]. J Am Coll Cardiol 2002
Mar 17-20; 39 (5 Suppl A) : 59A
53. Grube E, Silber SM, Hauptmann KE, et al. Taxus I: prospective,
randomized, double-blind comparison of NIRx TM stents coated with
paclitaxel in a polymer carrier in de-novo coronary lesions compared
with uncoated controls [abstract 2197]. Circulation 2001 Oct; 104 Suppl
II: 17
54. Grube E, Serruys PW. Safety and performance of a paclitaxel-eluting
stent for the treatment of in-stent restenosis: preliminary results of
the Taxus III trial [abstract no. 1174-15]. J Am Coll Cardiol 2002 Mar
17-20; 39 (5 Suppl A): 58A
55. Chao-Wei H, Wu D, Edelman E. physiological transport forces govern
drug distribution for stent-based delivery. Circulation 2001; 104:600-5
56. De Scheerder I, Yanming H, Dens J, et al. Treatment of in-stent
restenosis using paclitaxel eluting stents: a single centre pilot trial
[abstract 3503]. Circulation 2001 Oct; 104 Suppl II: 17
57. Liistro F, Colombo A. Late acute thrombosis after Paclitaxel eluting
stent implantation. Heart 2001 Sep; 86 (3): 262-4
58. Degertekin M, Regar E, Tanabe K, et al. Incidence of incomplete
stent apposition at six-month follow-up in the multicenter RAVEL trial
[abstract no. 823-5]. J Am Coll Cardiol 2002 Mar 17-20; 39 (5 Suppl A):
38A
59. Serruys PW, Abizaid A, Foley D, et al. Sirolimus-eluting stents
abolish neointimal hyperplasia in patients with in-stent restenosis:
late angiographic and intravascular ultrasound results {abstract no.
823-1]. J Am Coll Cardiol 2002 MAr 17-20; 39 ( 5 Suppl A): 37A
60. De la Fuente LM, Miano J, Mrad J, et al. Initial results of the
Quanam drug-eluting stent (QuaDS-QR-2): registry (BARDDS) in human
subjects. Catheter Cardiovasc Interv 2001 Aug; 53 (4): 480-8
|